Loading stock data…
$8.31+0.16 (+1.96%)
Harvard Bioscience, Inc.
Harvard Bioscience, Inc. in the Healthcare sector is trading at $8.31 with a market capitalization of $38M. Wall Street consensus targets $7.50 (1 analysts), implying a -9.7% move over the next 12 months. The stock is currently near its 52-week high of $9.40, remaining 31.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $20.45M↓ | $20.59M↓ | $23.73M↑ | $20.75M↓ | $22.73M |
| Gross Profit | $11.53M↓ | $12.02M↓ | $14.17M↑ | $12.24M↓ | $12.63M |
| Operating Income | -$619,000↓ | $245,000↓ | $1.93M↑ | -$939,000↓ | -$660,000 |
| Net Income | -$2.28M↓ | -$1.23M↑ | -$2.85M↑ | -$3.42M↓ | -$2.91M |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular techn...